SBRT showed improved LPFS over RFA in treating single recurrent small HCC, especially for tumors ≤2 cm. Both SBRT and RFA demonstrated similar PFS, OS, and safety profiles, with mild to moderate side ...

In patients with recurrent small hepatocellular carcinoma (HCC), stereotactic body radiotherapy (SBRT) demonstrated superior local progression-free survival (PFS) and tumor control at 3 years compared ...

Treatment outcomes of patients with mIDH1 cholangiocarcinoma in the United States. This is an ASCO Meeting Abstract from the 2026 ASCO Gastrointestinal Cancers Symposium. This abstract does not ...

CURE spoke with an expert about the potential positive effects of radiation therapy for patients with hepatocellular carcinoma. CURE recently spoke with Dr. Laura Dawson, a professor and chair of the ...

Stereotactic body radiation therapy (SBRT) has emerged as a cornerstone in the treatment of colorectal liver metastases, now featured in national and international guidelines from organizations such ...

The crossover of the bevacizumab and panitumumab survival curves in the PARADIGM study: A clue to time-related effects of bevacizumab on the risk of tumor progression. Risk of peritoneal recurrence ...

Intent-to-treat median PFS was 10.2 months with nivolumab/ipilimumab versus 6.3 months with added SBRT, with 12-month PFS 47.8% versus 34.9% (HR 1.20; P=.56). Per-protocol analysis after four ...

A phase 2 trial showed that combining targeted radiotherapy with PD-1 blockade and a bevacizumab biosimilar can elicit responses in advanced liver cancer.